Evolus sees FY24 revenue $255M-$265M, consensus $253.27M

Sees FY24 non-GAAP operating expenses $185M-$190M. As a result of the European Filler License agreement announced on December 20, 2023, the 2023 Operating Expense guidance range will increase from $153M-$158M to $160M-$165M. The issuance of 610,000 shares of the company’s common stock for the exclusive distribution rights for the UK and Europe will be recorded as IPR&D expense of up to $5.9M. Due to the capital efficient structure of our agreements with Symatese, the anticipated launch expenses associated with the Evolysse and Estyme dermal filler lines in the U.S. and Europe, respectively, are not anticipated to impact our expectation of achieving profitability in 2025. Evolus expects non-GAAP operating income to be positive in 2025 and continues to project its existing liquidity will fund current operations. During 2024, Evolus expects to broaden its global footprint by expanding into additional European countries with Nuceiva, most notably Australia and Spain. Evolus anticipates submitting Premarket Approval applications for the first two Evolysse dermal filler products with FDA by mid-year 2024 and expects regulatory approvals for the remaining Estyme dermal filler products in Europe in the second half of 2024.